May 5, 2014, Washington D.C. – Emmyon research was featured today in Chemical and Engineering News, a publication of the American Chemical Society. The article, “A Natural Green Boost for Muscles,” may be found here.
April 9, 2014, Coralville, IA. – Emmyon scientists Christopher Adams and Scott Ebert published a new paper today describing the discovery of tomatidine as a natural small molecule inhibitor of skeletal muscle atrophy. The paper, published in The Journal of Biological Chemistry, may be found here.
April 8, 2014, Coralville, IA. – Emmyon is pleased to announce that it has completed a licensing agreement with the University of Iowa. The agreement provides Emmyon an exclusive license to patent rights for a portfolio of small molecules. These small molecules, which include ursolic acid and tomatidine, increase skeletal muscle mass, strength and exercise capacity, and decrease skeletal muscle atrophy and obesity.
November 19, 2013, Cambridge, MA. – Emmyon’s Founder and President, Dr. Christopher Adams, presented a plenary lecture, “Discovering small-molecule inhibitors of skeletal muscle atrophy,“ at the Library of Integrated Network-Based Cellular Signatures (LINCS) Symposium. The Symposium was sponsored by the National Institutes of Health and held at the Broad Institute of MIT and Harvard. Dr. Adams’s lecture may be viewed and downloaded via the Broad Institute site on iTunesU. Additional information may be found here (http://www.broadinstitute.org/icmap/lincs_symposium/)
January 1, 2014, Coralville, IA. – Emmyon is pleased to announce that Dr. Scott Ebert has joined the company as a Research Scientist. A native of North Dakota, Dr. Ebert completed his Ph.D. training in the laboratory of Christopher Adams at the University of Iowa. As a graduate student, Dr. Ebert played a key role in early development of small molecules that are being further developed at Emmyon. Thus far, he has authored five peer-reviewed manuscripts concerning mechanisms and treatment of skeletal muscle atrophy, and he has been an inventor on one patent application.
July 1, 2013, Coralville, IA. – Emmyon is pleased to announce that it has been awarded a phase I SBIR award from the National Institute on Aging. The funding will support research to discover solutions for age-related skeletal muscle wasting, also known as sarcopenia.